基于靶向分子影像正电子发射断层扫描/计算机断层扫描受累模式的前列腺癌腹主动脉旁预防性淋巴结照射勾画指南的多机构开发与验证
多机构回顾性队列研究利用18F-氟环丁羧酸或18F-DCFPyL前列腺特异性膜抗原PET/CT,在559例开发集患者中确定覆盖≥95% PET阳性腹主动脉旁淋巴结的勾画指南,并在246例独立验证集中验证(97%淋巴结被覆盖)。
要点
- 勾画指南:主动脉左侧1.8 cm、下腔静脉右侧1.4 cm、主动脉/下腔静脉后方或至椎体7 mm、上界T11/T12椎体交界、前界主动脉/下腔静脉前4 mm、下界主动脉/下腔静脉分叉处。
- 开发集559例中76例(14%)有腹主动脉旁淋巴结转移证据。
- 验证集246例中31例有腹主动脉旁淋巴结转移,97%淋巴结被覆盖。
核心结论
- 利用分子PET/CT影像确定前列腺癌腹主动脉旁转移的解剖位置,开发了创建前列腺癌腹主动脉旁临床靶区的勾画指南。
- 腹主动脉旁放疗的最佳患者选择和临床获益仍不确定,但该结果有助于在实施腹主动脉旁放疗时勾画最佳靶区。
研究设计与样本
- 多机构回顾性队列研究,开发集559例接受18F-氟环丁羧酸或18F-DCFPyL前列腺特异性膜抗原PET/CT的前列腺癌患者。
- 独立验证集246例接受分子PET/CT的前列腺癌患者。
主要发现
- 开发集559例中76例(14%)有腹主动脉旁淋巴结转移证据。
- 将临床靶区扩展至主动脉左侧1.8 cm、下腔静脉右侧1.4 cm、主动脉/下腔静脉后方或至椎体7 mm、上界T11/T12椎体交界、前界主动脉/下腔静脉前4 mm、下界主动脉/下腔静脉分叉处,可覆盖≥95%的PET阳性腹主动脉旁淋巴结。
- 验证集246例中31例有腹主动脉旁淋巴结转移,97%淋巴结被覆盖,从而验证了该指南。
关键数值与推荐
- 勾画指南:主动脉左侧1.8 cm、下腔静脉右侧1.4 cm、主动脉/下腔静脉后方或至椎体7 mm、上界T11/T12椎体交界、前界主动脉/下腔静脉前4 mm、下界主动脉/下腔静脉分叉处。
- 开发集覆盖≥95%的PET阳性腹主动脉旁淋巴结。
- 验证集覆盖97%的淋巴结。
临床怎么用
- 原文未据此给出推荐。
局限性
- 腹主动脉旁放疗的最佳患者选择和临床获益仍不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Molecular imaging better identifies anatomic regions of metastatic spread of prostate cancer compared with conventional imaging, resulting in para-aortic (PA) nodal metastases being increasingly identified. Consequently, some radiation oncologists electively treat the PA lymph node region in patients with gross or high risk of PA nodal involvement. The anatomic locations of at-risk PA lymph nodes for prostate cancer are unknown. Our objective was to use molecular imaging to develop guidelines for the optimal delineation of the PA clinical target volume (CTV) in patients with prostate cancer. METHODS AND MATERIALS: We conducted a multi-institutional retrospective cohort study of patients with prostate cancer undergoing 18F-fluciclovine or 18F-DCFPyL prostate-specific membrane antigen positron emission tomography (PET)/computed tomography (CT). Images of patients with PET-positive PA nodes were imported into the treatment planning system, avid nodes were contoured, and measurements were taken in relation to anatomic landmarks. A contouring guideline that encompassed the location of ≥95% of PET-positive PA nodes was created using descriptive statistics and then validated in an independent data set. RESULTS: Five hundred fifty-nine patients had molecular PET/CT imaging in the development data set (78% 18F-fluciclovine, 22% prostate-specific membrane antigen). Seventy-six patients (14%) had evidence of PA nodal metastasis. We determined that expanding the CTV to 1.8 cm left of the aorta, 1.4 cm right of the inferior vena cava (IVC), 7 mm posterior to the aorta/IVC or to the vertebral body, and superiorly to the T11/T12 vertebral interface, with the anterior border 4 mm anterior to the aorta/IVC and inferior border at the bifurcation of the aorta/IVC, resulted in coverage of ≥95% of PET-positive PA nodes. When the guideline was used in the independent validation data set (246 patients with molecular PET/CT imaging, of whom 31 had PA nodal metastasis), 97% of nodes were encompassed, thereby validating our guideline. CONCLUSIONS: We used molecular PET/CT imaging to determine the anatomic locations of PA metastases to develop contouring guidelines for creating a prostate cancer PA CTV. Although the optimal patient selection and clinical benefits of PA radiation therapy remain uncertain, our results will aid in delineating the optimal target when PA radiation therapy is pursued.
引用
- Saripalli AL, Lee B, Adams W, et al. Multi-institutional Development and Validation of Contouring Guidelines for Para-aortic Elective Nodal Irradiation in Prostate Cancer Based on Patterns of Involvement on Targeted Molecular Imaging Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2023. PMID: 37201758. doi:10.1016/j.ijrobp.2023.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。